New drug duo aims to send tough leukemia into deep remission
NCT ID NCT03708003
Summary
This study tested a combination of two oral drugs, ibrutinib and venetoclax, for adults with chronic lymphocytic leukemia (CLL) that has returned or stopped responding to prior treatment. The goal was to see if using the drugs together could drive the cancer down to undetectable levels. Researchers hoped this deep remission might allow some patients to safely take a break from continuous treatment.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LEUKEMIA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
IOSI - Ospedale San Giovanni
Bellinzona, 6501, Switzerland
-
Inselspital
Bern, 3010, Switzerland
-
Kantonsspital Aarau
Aarau, CH-5001, Switzerland
-
Kantonsspital Graubünden
Chur, 7000, Switzerland
-
Kantonsspital Liestal
Liestal, CH-4410, Switzerland
-
Kantonsspital Münsterlingen
Münsterlingen, 8596, Switzerland
-
Kantonsspital Winterthur
Winterthur, 8401, Switzerland
-
Luzerner Kantonsspital
Lucerne, 6000, Switzerland
-
Spital STS AG Thun
Thun, 3600, Switzerland
-
Universitätsspital Basel
Basel, 4031, Switzerland
-
Universitätsspital Zürich
Zurich, 8091, Switzerland
Conditions
Explore the condition pages connected to this study.